Generate Biomedicines Inc (NASDAQ:GENB) Given Consensus Recommendation of “Buy” by Analysts

Generate Biomedicines Inc (NASDAQ:GENB) has been assigned a consensus rating of “Buy” from the five brokerages that are currently covering the company, MarketBeat.com reports. Five analysts have rated the stock with a buy recommendation. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $25.00.

A number of equities research analysts recently weighed in on the stock. The Goldman Sachs Group assumed coverage on shares of Generate Biomedicines in a report on Tuesday. They issued a “buy” rating and a $26.00 target price on the stock. Wall Street Zen raised Generate Biomedicines to a “hold” rating in a report on Saturday, March 14th. Piper Sandler began coverage on Generate Biomedicines in a research note on Tuesday. They issued an “overweight” rating and a $24.00 price objective for the company. Guggenheim began coverage on Generate Biomedicines in a report on Tuesday. They issued a “buy” rating and a $30.00 target price on the stock. Finally, Morgan Stanley started coverage on Generate Biomedicines in a research report on Tuesday. They set an “overweight” rating and a $20.00 target price on the stock.

Generate Biomedicines Stock Performance

GENB traded down $0.33 during trading on Tuesday, hitting $12.19. 50,185 shares of the company’s stock were exchanged, compared to its average volume of 693,201. Generate Biomedicines has a fifty-two week low of $11.00 and a fifty-two week high of $15.32.

Key Stories Impacting Generate Biomedicines

Here are the key news stories impacting Generate Biomedicines this week:

• Positive Sentiment: Guggenheim initiated coverage with a “buy” rating and a $30.00 price target (≈139.6% upside), the highest published target among today’s notes. Guggenheim Coverage
• Positive Sentiment: Goldman Sachs started coverage with a “buy” rating and a $26.00 price target (≈107.7% upside), another sizable bullish endorsement.
• Positive Sentiment: Piper Sandler initiated coverage with an “overweight” rating and a $24.00 price target (≈91.7% upside). Piper Sandler Coverage
• Positive Sentiment: Morgan Stanley initiated coverage with an “overweight” rating and a $20.00 price target (≈59.7% upside).
• Positive Sentiment: Cantor Fitzgerald initiated coverage with an “overweight” rating (no price target provided in the brief). Cantor Fitzgerald Coverage
• Neutral Sentiment: Reported short-interest data for March appears corrupted (shows 0 shares / NaN ratios), so there is no reliable public short-interest signal to explain intraday moves.

About Generate Biomedicines

Generate Biomedicines, Inc (NASDAQ: GENB) is a biotechnology company that applies machine learning and generative artificial intelligence to the design and discovery of novel therapeutics. The company develops computational platforms to create and optimize protein sequences and biological molecules with the goal of producing new medicines across a range of modalities. Its core activities center on algorithm-driven design, iterative experimental validation, and the translation of computational outputs into candidate therapeutic molecules.

Generate’s technology combines advanced computational models with high-throughput laboratory methods to accelerate discovery and improve the likelihood of producing viable drug candidates.